Wes Streeting is facing pressure to make a crucial decision regarding the implementation of universal testing for a severe muscle-wasting condition in newborns, which is now viewed as a political matter.
The Health Secretary recently met with Giles Lomax, the CEO of charity SMA UK, and former Little Mix singer Jesy Nelson, both of whom have twins diagnosed late with spinal muscular atrophy (SMA). Giles Lomax has directly appealed to Mr. Streeting in a publication, emphasizing the urgent need for action to prevent further delays in diagnosing babies with SMA.
SMA is a genetic disorder affecting the SMN1 gene, leading to the deterioration of nerve cells responsible for muscle movement. Early detection through newborn screening can enable timely interventions that can effectively treat the condition.
Currently, three NHS treatments are available that can either correct the faulty gene or provide the essential protein to prevent muscle degeneration, serving as a potential cure if administered at birth.
Each year, an estimated 33 babies in the UK are diagnosed late with SMA, resulting in the need for mobility aids and specialized care. The delay in diagnosis significantly impacts the quality of life for affected infants.
Mr. Streeting is considering expanding an NHS pilot program to include SMA screening for all newborns as part of routine testing. However, current plans entail excluding a significant portion of newborns in England to serve as a control group, a decision criticized by experts as unethical.
Advocates for SMA screening argue that a nationwide approach is necessary to ensure equitable access to early detection and treatment. The urgency of the situation calls for swift action to prevent further cases of late diagnosis and associated complications.
The UK National Screening Committee previously opted against adding SMA to the newborn screening program but with advancements in treatment, the necessity for comprehensive screening is increasingly evident.
While a full screening rollout may not occur until 2031 as per the current schedule, individual regions like Scotland have taken proactive steps to include SMA screening in routine testing. The disparity in screening protocols across the UK highlights the need for a unified approach to newborn screening.
Efforts are underway to conduct a large-scale trial for SMA screening across the NHS, indicating progress towards a potential national screening program. The commitment to improving access to treatments for SMA reflects a collective goal of ensuring better outcomes for affected children.
